The U.S. Senate has officially confirmed Dr. Marty Makary as Commissioner of the Food and Drug Administration (FDA), marking a major step forward in President Trump’s overhaul of federal health agencies. Dr. Makary, a nationally respected physician, professor, and medical reform advocate, brings a strong record of innovation, independence, and patient-centered leadership to the role.
Makary’s confirmation follows a 14-9 vote in the Senate HELP Committee, and a successful floor vote that solidified his appointment despite opposition from Democrats and entrenched bureaucratic interests.
A Surgeon, Scholar, and Voice for Transparency
Dr. Makary serves as a professor at Johns Hopkins School of Medicine and is a leader in the field of surgical oncology and gastrointestinal surgery. He also holds the Mark Ravitch Chair in Gastrointestinal Surgery and has pioneered key innovations in patient safety, including the development of a surgical checklist now used globally.
He has been a vocal advocate for healthcare transparency, lower drug prices, and challenging bureaucratic inefficiencies—stances that align closely with Trump’s America First healthcare agenda.
Facing Key Issues at the FDA
As the new FDA Commissioner, Dr. Makary will confront several high-profile issues that will define the future of U.S. health policy:
Abortion Pill Oversight: The regulation of mifepristone, a widely used abortion pill, is expected to remain a flashpoint. While President Trump has said he won’t move to restrict the drug federally, Makary’s leadership will be pivotal in restoring scientific integrity and regulatory balance after years of partisan influence under prior administrations.
Vaccine Policy Reform: Makary will also take charge of rebuilding public trust in vaccine oversight. During his confirmation hearings, he criticized the politicization of science under the Biden-era FDA and vowed to ensure open, evidence-based decision-making going forward.
A New Direction for U.S. Health Leadership
Makary joins a growing team of Trump-appointed health officials, including Dr. Jay Bhattacharya, now heading the National Institutes of Health (NIH). Together, they represent a pro-science, anti-politicization movement within the Trump administration that seeks to restore trust, transparency, and results to America’s public health institutions.
President Trump praised the confirmation, saying Dr. Makary would bring “common sense, courage, and clinical credibility back to the FDA.”
Bottom Line
Dr. Marty Makary’s confirmation is more than a personnel move—it’s a mandate for reform. As he steps into the role, Americans can expect a focus on accountability, medical freedom, and honest science—values sorely lacking in recent years. Under his leadership, the FDA is poised to return to its rightful role: serving the American people—not special interests or political agendas.
The post Senate Confirms Dr. Marty Makary as Trump’s FDA Chief appeared first on Real News Now.
About Author
